Atorvastatin at reperfusion reduces myocardial infarct size in mice by activating enos in bone Marrow-Derived cells

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Tian, Yikui ^a   Linden, Joel ^a   French, Brent A ^a   Yang, Zequan ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DYE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PHTHALO BLUE; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; NOS3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; REPERFUSION INJURY; TRANSCRIPTION INITIATION; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; HEART VENTRICLE; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY;

ANIMALS; ATORVASTATIN CALCIUM; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CARDIOTONIC AGENTS; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; HEART VENTRICLES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHIL INFILTRATION; NITRIC OXIDE SYNTHASE TYPE III;

EID: 84960153707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114375     Document Type: Article

References (45)

1. Olsson AG, Schwartz GG (2002) Early initiation of treatment with statins in acute coronary syndromes. Ann Med 34: 37-41.
2. Waters D, Schwartz GG, Olsson AG (2001) The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: A new frontier for statins? Curr Control Trials Cardiovasc Med 2: 111-114.
3. Wright DG, Lefer DJ (2005) Statin mediated protection of the ischemic myocardium. Vascul Pharmacol 42: 265-270.
4. Leung WH, Lau CP, Wong CK (1993) Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 341: 1496-1500.
5. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, et al. (2003) Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 93: E98-103.
6. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, et al. (2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933-1935.
7. Olsson AG, Schwartz GG, Jonasson L, Linderfalk C (2002) Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiol Scand 176: 147-150.
8. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, et al. (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111: 412-419.
9. Bauer T, Bohm M, Zahn R, Junger C, Koeth O, et al. (2009) Effect of chronic statin pretreatment on hospital outcome in patients with acute non-ST-elevation myocardial infarction. J Cardiovasc Pharmacol 53: 132-136.
10. Chen M, Li H, Wang Y (2013) Protection by atorvastatin pretreatment in patients undergoing primary percutaneous coronary intervention is associated with the lower levels of oxygen free radicals. J Cardiovasc Pharmacol 62: 320-324.
11. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, et al. (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49: 1272-1278.
12. Hahn JY, Kim HJ, Choi YJ, Jo SH, Kim HJ, et al. (2011) Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 162: 1026-1033.
13. Bell RM, Yellon DM (2003) Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515.
14. Andreadou I, Farmakis D, Prokovas E, Sigala F, Zoga A, et al. (2012) Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: Effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc Res 94: 501-509.
15. Li XD, Yang YJ, Geng YJ, Zhao JL, Zhang HT, et al. (2012) Phosphorylation of endothelial NOS contributes to simvastatin protection against myocardial no-reflow and infarction in reperfused swine hearts: Partially via the PKA signaling pathway. Acta Pharmacol Sin 33: 879-887.
16. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, et al. (2000) Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31: 2442-2449.
17. Jayachandran M, Miller VM (2003) Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets 14: 75-81.
18. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, et al. (2003) Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 112: 883-891.
19. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, et al. (2005) Infarct-sparing effect of A2Aadenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111: 2190-2197.
20. Xu Y, Huo Y, Toufektsian MC, Ramos SI, Ma Y, et al. (2006) Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 290: H692-H699.
21. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, et al. (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377: 239-242.
22. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A (2001) Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103: 2248-2253.
23. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, et al. (2004) Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-355.
24. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, et al. (1999) Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100: 178-184.
25. Zuidema MY, Zhang C (2010) Ischemia/reperfusion injury: The role of immune cells. World J Cardiol 2: 325-332.
26. Barrabes JA, Inserte J, Mirabet M, Quiroga A, Hernando V, et al. (2010) Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost 104: 128-135.
27. Kupatt C, Wichels R, Horstkotte J, Krombach F, Habazettl H, et al. (2002) Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion. J Leukoc Biol 72: 455-461.
28. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, et al. (1998) Platelet-endothelial cell interactions during ischemia/reperfusion: The role of P-selectin. Blood 92: 507-515.
29. Mirabet M, Garcia-Dorado D, Inserte J, Barrabes JA, Lidon RM, et al. (2002) Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol 283: H1134-H1141.
30. Jones SP, Gibson MF, Rimmer DM 3rd, Gibson TM, Sharp BR, et al. (2002) Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40: 1172-1178.
31. Jones SP, Lefer DJ (2001) Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 173: 139-143.
32. Marzilli M (2010) Pleiotropic effects of statins: Evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs 10 Suppl 1: 3-9.
33. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, et al. (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450-1457.
34. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, et al. (2004) Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287: H560-H566.
35. Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, et al. (2005) HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 96: 1185-1192.
36. Teupser D, Bruegel M, Stein O, Stein Y, Thiery J (2001) HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem Biophys Res Commun 289: 838-844.
37. Gaddam V, Li DY, Mehta JL (2002) Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 7: 247-253.
38. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, et al. (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 96: 11507-11512.
39. Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, et al. (2008) The role of eNOS, iNOS, and NFkappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 295: H343-H351.
40. Guo Y, Sanganalmath SK, Wu W, Zhu X, Huang Y, et al. (2012) Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury. Basic Res Cardiol 107: 253.
41. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, et al. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350-356.
42. Rork TH, Wallace KL, Kennedy DP, Marshall MA, Lankford AR, et al. (2008) Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 295: H1825-H1833.
43. Rikitake Y, Liao JK (2005) Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232-1235.
44. Mensah K, Mocanu MM, Yellon DM (2005) Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45: 1287-1291.
45. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, et al. (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8: 473-479.